II
TXG icon

IFM Investors’s 10x Genomics TXG Stock Holding History

IFM Investors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,549
Closed -$879K – 655
2022
Q1 		$879K Buy
11,549
+1,919
+20% +$168K 0.01% 591
2021
Q4 		$1.43M Buy
9,630
+387
+4% +$59.3K 0.03% 536
2021
Q3 		$1.35M Sell
9,243
-141
-2% -$24.2K 0.03% 528
2021
Q2 		$1.84M Buy
9,384
+2,589
+38% +$469K 0.04% 472
2021
Q1 		$1.23M Buy
6,795
+434
+7% +$74.9K 0.03% 498
2020
Q4 		$901K Buy
+6,361
New +$923K 0.03% 523

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

IFM Investors's TXG Position: Q2 2022 in Review

IFM Investors sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 11,549 shares — an estimated $879K sold.

IFM Investors first reported a position in TXG in Q4 2020 and held it in 6 quarters. The position peaked at $1.84M in Q2 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • IFM Investors reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • IFM Investors sold 11,549 10x Genomics shares in Q2 2022, an estimated $879K.
  • IFM Investors first reported a position in 10x Genomics in Q4 2020 and held it in 6 quarters.
  • IFM Investors's 10x Genomics position peaked at $1.84M in Q2 2021.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on IFM Investors's 13F filing for Q2 2022, filed 15 Jul 2022.